Literature DB >> 20170768

Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Stephen H Gregory1, Wilbur H Chen, Stephanie Mott, John E Palardy, Nicholas A Parejo, Sara Heninger, Christine A Anderson, Andrew W Artenstein, Steven M Opal, Alan S Cross.   

Abstract

Francisella tularensis is a category A select agent. J5dLPS/OMP is a novel vaccine construct consisting of detoxified, O-polysaccharide side chain-deficient, lipopolysaccharide non-covalently complexed with the outer membrane protein of N. meningitidis group B. Immunization elicits high-titer polyclonal antibodies specific for the highly-conserved epitopes expressed within the glycolipid core that constitutes gram-negative bacteria (e.g., F. tularensis). Mice immunized intranasally with J5dLPS/OMP exhibited protective immunity to intratracheal challenge with the live vaccine strain, as well as the highly-virulent SchuS4 strain, of F. tularensis. The efficacy of J5dLPS/OMP vaccine suggests its potential utility in immunizing the general population against several different gram-negative select agents concurrently. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20170768      PMCID： PMC2847053          DOI： 10.1016/j.vaccine.2010.01.067

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  50 in total

1.  Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig.

Authors:  H T EIGELSBACH; C M DOWNS
Journal:  J Immunol       Date:  1961-10       Impact factor: 5.422

2.  Tularemia vaccine study. II. Respiratory challenge.

Authors:  S SASLAW; H T EIGELSBACH; J A PRIOR; H E WILSON; S CARHART
Journal:  Arch Intern Med       Date:  1961-05

3.  Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.

Authors:  A S Cross; S M Opal; H S Warren; J E Palardy; K Glaser; N A Parejo; A K Bhattacharjee
Journal:  J Infect Dis       Date:  2001-03-08       Impact factor: 5.226

4.  Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines.

Authors:  Susan M Twine; Mireille D Petit; Hua Shen; Nadia C S Mykytczuk; John F Kelly; J Wayne Conlan
Journal:  Biochem Biophys Res Commun       Date:  2006-06-09       Impact factor: 3.575

5.  Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.

Authors:  Steven M Opal; John E Palardy; Wilbur H Chen; Nicolas A Parejo; Apurba K Bhattacharjee; Alan S Cross
Journal:  J Infect Dis       Date:  2005-11-10       Impact factor: 5.226

6.  Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors.

Authors:  Adeline M Hajjar; Megan D Harvey; Scott A Shaffer; David R Goodlett; Anders Sjöstedt; Helen Edebro; Mats Forsman; Mona Byström; Mark Pelletier; Christopher B Wilson; Samuel I Miller; Shawn J Skerrett; Robert K Ernst
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

7.  Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence.

Authors:  M Fulop; R Manchee; R Titball
Journal:  FEMS Immunol Med Microbiol       Date:  1996-03

8.  Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis.

Authors:  Meenakshi Malik; Chandra Shekhar Bakshi; Bikash Sahay; Aaloki Shah; Steven A Lotz; Timothy J Sellati
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

Review 9.  Tularaemia: bioterrorism defence renews interest in Francisella tularensis.

Authors:  Petra C F Oyston; Anders Sjostedt; Richard W Titball
Journal:  Nat Rev Microbiol       Date:  2004-12       Impact factor: 60.633

10.  Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia.

Authors:  M Fulop; R Manchee; R Titball
Journal:  Vaccine       Date:  1995-09       Impact factor: 3.641
View more
  4 in total

1.  Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.

Authors:  Maurílio F Santos; Roger R C New; Gabrielle R Andrade; Christiane Y Ozaki; Osvaldo A Sant'Anna; Lucia Mendonça-Previato; Luis R Trabulsi; Marta O Domingos
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

2.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

3.  Chemical synthesis and immunological evaluation of the inner core oligosaccharide of Francisella tularensis.

Authors:  Thomas J Boltje; Wei Zhong; Jin Park; Margreet A Wolfert; Wangxue Chen; Geert-Jan Boons
Journal:  J Am Chem Soc       Date:  2012-08-16       Impact factor: 15.419

4.  Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System.

Authors:  Sukalyani Banik; Ahd Ahmed Mansour; Ragavan Varadharajan Suresh; Sherri Wykoff-Clary; Meenakshi Malik; Alison A McCormick; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.